Japan’s Takeda buys PvP Biologics in $330m deal
PvP Biologics has been acquired following the conclusion of Phase 1 proof-of-mechanism study of investigational medicine TAK-062 (Kuma062), which is being developed to treat uncontrolled celiac disease. The